- Home
- SPRO vs CNTY Comparison
SPRO vs CNTY Comparison
Compare SPRO & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- CNTY
- Stock Information
- Founded
- SPRO 2013
- CNTY 1992
- Country
- SPRO United States
- CNTY United States
- Employees
- SPRO N/A
- CNTY N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- CNTY Hotels/Resorts
- Sector
- SPRO Health Care
- CNTY Consumer Discretionary
- Exchange
- SPRO Nasdaq
- CNTY Nasdaq
- Market Cap
- SPRO 74.0M
- CNTY 80.7M
- IPO Year
- SPRO 2017
- CNTY 1993
- Fundamental
- Price
- SPRO $1.32
- CNTY $2.44
- Analyst Decision
- SPRO Strong Buy
- CNTY Buy
- Analyst Count
- SPRO 3
- CNTY 3
- Target Price
- SPRO $7.00
- CNTY $4.00
- AVG Volume (30 Days)
- SPRO 124.2K
- CNTY 67.6K
- Earning Date
- SPRO 08-05-2024
- CNTY 08-08-2024
- Dividend Yield
- SPRO N/A
- CNTY N/A
- EPS Growth
- SPRO N/A
- CNTY N/A
- EPS
- SPRO 0.33
- CNTY N/A
- Revenue
- SPRO $118,459,000.00
- CNTY $587,389,000.00
- Revenue This Year
- SPRO N/A
- CNTY $9.94
- Revenue Next Year
- SPRO N/A
- CNTY $9.31
- P/E Ratio
- SPRO $4.04
- CNTY N/A
- Revenue Growth
- SPRO 118.43
- CNTY 27.26
- 52 Week Low
- SPRO $0.99
- CNTY $1.94
- 52 Week High
- SPRO $1.89
- CNTY $6.14
- Technical
- Relative Strength Index (RSI)
- SPRO 47.38
- CNTY 51.61
- Support Level
- SPRO $1.30
- CNTY $2.31
- Resistance Level
- SPRO $1.37
- CNTY $2.52
- Average True Range (ATR)
- SPRO 0.08
- CNTY 0.10
- MACD
- SPRO 0.00
- CNTY 0.02
- Stochastic Oscillator
- SPRO 51.56
- CNTY 73.33
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurant, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.